Possible breakout, page-73

Thanks for everyones input. I understand the issues raised. My point is that from what little information we have been provided the trial seems under powered from a statistical sense. I am expecting the word "trend" to be used a lot to describe the results and "encouraging". Basically when a clinician heres that from a trial we stop listening. I do not think this necessarily reflects on the drug just that this particular trial seems quixotic from a clinical standpoint to say the least. Incredible results would show statistical significance and I certainly hope for them. I would also say that this opinion, whilst certainly not amateurish, is based on limited information. As I am a long suffering holder, I'm pretty agnostic at the moment.

On a more positive note. It does seem like the company is setting up to enter an up trend with the potential for a "golden cross" looming. Fingers crossed.